Press Release


CEA-IgM in colon cancer early stage detection assessed by AIGO in a multicenter prospective study

The Italian Association for Hospital Gastroenterologists (AIGO) has organized a multicenter, prospective, observational study to assess the diagnostic value of the novel biomarker CEA-IgM (Xeptagen) in patients affected by colon cancer (CRC). The study, coordinated by Dr. Sergio Morini, Gastroenterology Unit, ASL Roma A and by Dr. Renato Cannizzaro, Gastroenterology Unit, CRO Aviano in collaboration with major Italian clinical centres will enrol 150 colon cancer patients. Additional expected study outcomes are the evaluation of patient compliance for CEA-IgM test compared to FIT.